Tech Center 1600 • Art Units: 1634 1682
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18470187 | METHODS AND COMPOSITIONS FOR QUANTIFYING IMMUNE CELL DNA | Non-Final OA | GUARDANT HEALTH, INC. |
| 18245183 | ACTIVATORS OF TYPE III CAS PROTEINS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | Non-Final OA | The Regents of the University of California |
| 18067192 | Methods of Using Multi-Tissue Organoids | Non-Final OA | The University of Chicago |
| 17811677 | DETECTING GASTROINTESTINAL NEOPLASMS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18444227 | COMPOSITIONS AND METHODS FOR MAKING AND USING AN IMMORTALIZED LIBRARY | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17908809 | FIT-FLARES FOR DETECTION OF INTRACELLULAR ANALYTES IN LIVE CELLS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17630135 | NUCLEIC ACID CONSTRUCTS AND RELATED METHODS FOR NANOPORE READOUT AND SCALABLE DNA CIRCUIT REPORTING | Final Rejection | University of Washington |
| 17792612 | METHODS FOR DIAGNOSING HEPATOCELLULAR CARCINOMA | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18036215 | Immunotherapy Response Signature | Non-Final OA | Caris MPI, Inc. |
| 18261366 | METHODS OF DETECTING HIGH RISK BARRETT'S ESOPHAGUS WITH DYSPLASIA, AND ESOPHAGEAL ADENOCARCINOMA | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | Non-Final OA | Kite Pharma, Inc. |
| 17786397 | METHODS AND COMPOSITIONS FOR MONITORING AND DIAGNOSING HEALTHY AND DISEASE STATES | Final Rejection | Duke University |
| 17774424 | BIOMARKER COMPOSITION FOR DIAGNOSING OR PREDICTING PROGNOSIS OF THYROID CANCER, COMPRISING PREPARATION CAPABLE OF DETECTING MUTATION IN PLEKHS1 GENE, AND USE THEREOF | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17783300 | METHOD FOR WHOLE GENOME SEQUENCING OF PICOGRAM QUANTITIES OF DNA | Final Rejection | Oxford University Innovation Limited |
| 17783984 | METHOD FOR ASSESSING RISK OF DEVELOPING HEPATOCELLULAR CARCINOMA FROM NON-ALCOHOLIC STEATOHEPATITIS | Final Rejection | KEIO UNIVERSITY |
| 18629059 | FLUIDICS SYSTEMS FOR SEQUENTIAL DELIVERY OF REAGENTS | Final Rejection | Life Technologies Corporation |
| 18806109 | Unsupervised Machine Learning Methods | Final Rejection | AMPEL BioSolutions, LLC |
| 17904741 | DYNAMIC FRET-BASED SINGLE-MOLECULE SENSOR FOR ULTRASENSITIVE DETECTION OF NUCLEIC ACIDS | Final Rejection | VIRGINIA COMMONWEALTH UNIVERSITY |
| 18549333 | METHOD FOR DETECTING OR QUANTIFYING PHOTOAGED CELLS, APPLICATION OF SAME, AND METHOD FOR PREPARING PHOTOAGED CELLS | Non-Final OA | Ushio Denki Kabushiki Kaisha |
| 18208140 | METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES | Non-Final OA | REVVITY HEALTH SCIENCES, INC. |
| 17393609 | DETECTING CANCER, CANCER TISSUE OF ORIGIN, AND/OR A CANCER CELL TYPE | Final Rejection | GRAIL, LLC |
| 18253803 | ENCODED ASSAYS | Non-Final OA | PLENO, INC. |
| 18488850 | EPIGENETIC ANALYSIS OF CELL THERAPY AND RELATED METHODS | Final Rejection | Juno Therapeutics, Inc. |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Non-Final OA | SEAGEN INC. |
| 18130852 | MARKER FOR RESPONSE TO PD-1/PD-L1 IMMUNOTHERAPY | Non-Final OA | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. |
| 18019470 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Non-Final OA | Insight Molecular Diagnostics Inc. |
| 17769173 | REACTIVE AFFINITY PROBE-INTERACTION DISCOVERY PLATFORM | Non-Final OA | Jnana Therapeutics Inc. |
| 17252619 | SIALIC ACID TRANSPORTER PROTEINS AS BIOMARKERS AND DRUG TARGETS | Final Rejection | Quadram Institute Bioscience |
| 18252634 | PANEL OF MIRNA BIOMARKERS FOR DIAGNOSIS OF OVARIAN CANCER, METHOD FOR IN VITRO DIAGNOSIS OF OVARIAN CANCER, USES OF PANEL OF MIRNA BIOMARKERS FOR IN VITRO DIAGNOSIS OF OVARIAN CANCER AND TEST FOR IN VITRO DIAGNOSIS OF OVARIAN CANCER | Non-Final OA | UNIWERSYTET MEDYCZNY W BIALYMSTOKU |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy